Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 9/20 | 0.44 |
| ▸ | FUCA1 | P04066 | 4/20 | 0.44 |
| ▸ | GLA | P06280 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | GLB1 | P16278 | 2/20 | 0.44 |
| ▸ | MAN1B1 | Q9UKM7 | 1/20 | 0.42 |
| ▸ | PYGL | P06737 | 1/20 | 0.34 |
| ▸ | GBA2 | Q9HCG7 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1749164 | 1.00 | GBA1 (0.44) | GBA1FUCA1GLAGAAGLB1 | |
| SCHEMBL27644253 | 1.00 | GBA1 (0.44) | GBA1FUCA1GLAGAAGLB1 | |
| SCHEMBL1749165 | 1.00 | GBA1 (0.44) | GBA1FUCA1GLAGAAGLB1 | |
| SCHEMBL2304547 | 0.83 | GBA1 (0.44) | GBA1FUCA1GLAGAAGLB1 | |
| SCHEMBL2304542 | 0.83 | GBA1 (0.44) | GBA1FUCA1GLAGAAGLB1 | |
| SCHEMBL2304538 | 0.83 | GBA1 (0.44) | GBA1FUCA1GLAGAAGLB1 | |
| SCHEMBL10374455 | 0.81 | FUCA1 (0.40) | FUCA1 | |
| SCHEMBL16819055 | 0.76 | FUCA1 (0.41) | GBA1FUCA1GLAGAAGLB1 | |
| SCHEMBL16819065 | 0.76 | FUCA1 (0.41) | GBA1FUCA1GLAGAAGLB1 | |
| SCHEMBL2244209 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7968550-B2 | Substituted N-aryl heterocycles, process for their preparation and their use as medicaments | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2011-06-28 | — | — | US | disclosed |
| CN-100506792-C | Substituted N-aryl heterocycles, method for the production thereof and their use as medicaments | AVENTIS PHARMA GMBH (DE) | 2009-07-01 | — | — | CN | disclosed |
| US-20070207991-A1 | Substituted N-aryl Heterocycles, Process For Their Preparation and Their Use As Medicaments | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-09-06 | — | — | US | disclosed |
| US-7223788-B2 | therapy for eating disorders, anorexigenic agents, antidiabetic agents, reducing weight in mammals, circadian rhythm disease, psychological disorders | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-05-29 | — | — | US | disclosed |
| CN-1774418-A | Substituted N-arylheterocycles, method for production and use thereof as medicaments | AVENTIS PHARMA GMBH (DE) | 2006-05-17 | — | — | CN | disclosed |
| US-20040220191-A1 | Substituted N-aryl heterocycles, process for their preparation and their use as medicaments | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220191-A1 | Substituted N-aryl heterocycles, process for their preparation and their use as medicaments | CYP11B2, CYP11B1, CYP1A1 | GBA1 1832/4885FUCA1 2220/4885GLA 2872/4885 |
| US-20070207991-A1 | Substituted N-aryl Heterocycles, Process For Their Preparation and Their Use As Medicaments | CYP11B2, CYP11B1, NQO1 | GBA1 2105/4885FUCA1 2702/4885GLA 2866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.